Teva commits to OTC as it winds up alliance

Teva still sees OTC medicines as a “growing and long-term key business”, despite announcing plans with Procter & Gamble (P&G) to end the pair’s six-year ‘PGT Healthcare’ OTC joint venture, according to the Israeli firm. The decision – made after “the companies concluded that their priorities and strategies are no longer closely aligned” – comes as Teva is executing a major structural overhaul instigated by chief executive officer Kåre Schultz (Generics bulletin, 1 December 2017, page 1), and is “not expected to have a material impact on Teva’s 2018 financial outlook”.

Teva still sees OTC medicines as a “growing and long-term key business”, despite announcing plans with Procter & Gamble (P&G) to end the pair’s six-year ‘PGT Healthcare’ OTC joint venture, according to the Israeli firm. The decision – made after “the companies concluded that their priorities and strategies are no longer closely aligned” – comes as Teva is executing a major structural overhaul instigated by chief executive officer Kåre Schultz (Generics bulletin, 1 December 2017, page 1), and is “not expected to have a material impact on Teva’s 2018 financial outlook”.

At the same time, P&G has signed a deal to acquire Merck KGaA’s Consumer Health business for C3.4 billion (US$4.2...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Lupin Looks To Expand In China With Respiratory Alliance

 
• By 

Lupin is planning to expand its footprint in China through a deal for a tiotropium dry powder inhaler with local player Sino Universal Pharmaceuticals.

Welch Heads Up Par Ahead Of Planned Spin-Off After Endo-Mallinckrodt Merger

 
• By 

As Endo and Mallinckrodt continue to work towards consummating the merger they announced earlier this year, the pair have revealed further organizational details of their combined generics and sterile injectables business, which is set to be spun off after the merger is complete.

Reshaped Xbrane Allies With OneSource For Commercial Biosimilar Manufacturing

 
• By 

Xbrane Biopharma is partnering with India’s OneSource Specialty Pharma to manufacture its biosimilars, including its much-delayed ranibizumab product Ximluci. The move follows a SEK240m funding round and strategic refocus on commercialization after divesting key R&D assets to Alvotech.

Corapharm Deal Offers South-East Europe Opportunity For mAbxience

 
• By 

Hot on the heels of a recent alliance in Italy, biosimilars developer mAbxience has struck another deal – this time partnering with Corapharm in south-east Europe.

More from Business

Replacements Named As Eder Leaves Stada And Medicines For Europe

 
• By 

Stephan Eder has left Stada and stepped down as president of Medicines for Europe, with the company announcing plans for his replacement and the association naming Polpharma CEO Markus Sieger as the association’s new interim president.

Reshaped Xbrane Allies With OneSource For Commercial Biosimilar Manufacturing

 
• By 

Xbrane Biopharma is partnering with India’s OneSource Specialty Pharma to manufacture its biosimilars, including its much-delayed ranibizumab product Ximluci. The move follows a SEK240m funding round and strategic refocus on commercialization after divesting key R&D assets to Alvotech.

Regeneron Monitoring Eylea Biosimilar Closely Following Innovative Setbacks

 
• By 

Regeneron says it is closely watching Amgen’s Pavblu 2mg aflibercept biosimilar, which is gaining traction via financial incentives to physicians as “the only differentiator” to its Eylea reference brand. Meanwhile, Regeneron is aiming to boost Eylea HD uptake amid regulatory setbacks.